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Tyrosine hydroxylaseSpontaneously hypertensive rats (SHR) are known to have cardiac noradrenergic hyperactivity due to an
impaired nitric oxide (NO)–cGMP pathway. We hypothesized that dietary L-arginine supplementation may
correct this autonomic phenotype. Male SHR and Wistar Kyoto rats (WKY) aged 16–18 weeks were given L-
arginine (10 g/L in drinking water) for 1 week. Separate control groups received no supplementation. The
SHR control had a signiﬁcantly lower plasma L-arginine than WKY control, but this was increased to a
comparable level following L-arginine. Atrial cGMP was lower in the SHR control compared with the WKY
control (2.4±0.4 pmol/mg vs 3.9±0.5 pmol/mg, pb0.05), but increased to 4.1±0.5 pmol/mg protein
(n=8, pb0.05) with L-arginine. Evoked [3H]norepinephrine release in isolated spontaneously beating right
atria from the SHR control (328±19%, n=19) was 28% higher than the WKY control (256±20%, n=14,
pb0.05), but was reduced to 258±11% with L-arginine feeding (n=24, pb0.01). Soluble guanylyl cyclase
(sGC) inhibition caused a greater increase of evoked norepinephrine release in the L-arginine fed SHR
compared with the non-fed SHR. L-arginine feeding did not reduce evoked norepinephrine release in the
WKY. In-vitro heart rate response to exogenous norepinephrine (0.1–5 μmol/L) was similar between L-
arginine fed (n=13) and non-fed SHR (n=10), suggesting that L-arginine supplementation worked pre-
synaptically. Myocardial tyrosine hydroxylase protein was decreased in SHR following L-arginine
supplementation, providing a link to reduced synthesis of norepinephrine. In conclusion, L-arginine
supplementation corrects local cardiac noradrenergic hyperactivity in the SHR, probably via increased pre-
synaptic substrate availability of NOS–sGC–cGMP pathway and reduced tyrosine hydroxylase levels.© 2009 Elsevier Inc. Open access under CC BY license.1. IntroductionImpairment of cardiac autonomic function characterises many
cardiovascular disorders. Its presence is associated with adverse
clinical outcome, even in apparently normal subjects [1,2]. It is well
established that hypertension is strongly associated with noradrener-
gic hyperactivity, with increased central sympathetic output as well as
elevated plasma epinephrine and norepinephrine (NE)1 levels [3–5].
Although the exact causal role of the sympathetic activation remains
to be clariﬁed, disruption of nitric oxide (NO)–cyclic guonosine
monophosphate (cGMP) pathway modulating the sympathetic func-
tion either centrally or peripherally has been implicated [6–8]. We
recently demonstrated that a signiﬁcant component of cardiac
sympathetic hyperactivity in spontaneously hypertensive rats (SHR)
occurs at the end organ level with impaired NO–cGMP signalling, and
that gene transfer with a noradrenergic cell speciﬁc promoter coupled
to neuronal nitric oxide synthase (nNOS) could increase thecience Centre, Department of
, Parks Road, OX1 3PT Oxford,
170.
aterson).
 license.production of cGMP with resultant inhibition of sympathetic
neurotransmission in atria [9]. However, gene transfer involving
adenoviruses is an invasive procedure and poses considerable hurdles
to widespread use in clinical practice. We therefore explored a simple
non-invasive method of augmenting the NO–cGMP signalling and
examined its effect on local cardiac noradrenergic neurotransmission
in the SHR in order to provide further basis for future clinical trials.
L-arginine (L-arg) is the sole substrate of the enzyme NOS in the
synthesis of NO [10,11]. Intracellular concentrations of L-arg normally
greatly exceed the level that is required for maximal enzyme kinetics
of NOS; the Michaelis constant (Km) of L-arg for NOS is 2.9 μmol/L
whereas the intracellular level of L-arg in-vivo is 0.8–2 mmol/L, with
plasma concentration in the region of 60–350 μmol/L [12,13]. Despite
this, L-arg supplementation has been shown to improve endothelial
function, reduce atherosclerosis progression, and alter autonomic
function; all consistent with enhanced NO synthesis [12,14,15]. This is
termed the L-arginine paradox, and can probably be best explained by
compartmentalisation of NOS and a relative L-arg deﬁciency rather
than an absolute one.
In the present study, we showed that oral L-arg supplementation
could reduce local cardiac noradrenergic hyperactivity in the SHR by
increasing pre-synaptic substrate availability of the NOS–sGC–cGMP
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of reduction in cardiac tyrosine hydroxylase levels.
2. Materials and methods
2.1. Animals
Male SHR aged 16–18 weeks and Wistar Kyoto rats (WKY) were
sourced from Harlan, UK, and kept under standard laboratory
conditions. L-arg supplemented groups were given L-arg (Sigma, UK)
in drinking water (10 g/L water) for 1 week. Control groups received
no supplementation but otherwise have free access to water and rat
chow. The experiments conformed to the Animals (Scientiﬁc
Procedures) Act 1986 (UK) and the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996).
2.2. Heart rate and blood pressure measurement
The heart rate and arterial blood pressure were measured
invasively as a terminal procedure (prior to in-vitro physiological
experiments) on some rats. Brieﬂy the rat was ventilated under
anaesthesia (3% isoﬂurane and 100% oxygen) and its left carotid artery
was cannulated with a 3F portex cannula. The cannula was then
connected to a pressure transducer and data was acquired using a
Biopac M100 system connected to a Dell P4 computer and run on the
AcqKnowledge 3.7.3 software. After an equilibration period of at least
10 min at lower isoﬂurane concentration (1.5%), the heart rate and
blood pressure readings were taken. Following completion of the
hemodynamic measurement, the animals were euthanised with
intraperitoneal injection of pentobarbitone. Blood samples were
taken via intraventricular puncture and the whole heart removed.
Blood samples were immediately spun at 5000 rpm for 10 min. Red
blood cell and plasma (in heparinised tube) were separated and
stored, as was serum. These were snapped frozen in liquid nitrogen
before being stored at −80 °C for long term.
2.3. Local norepinephrine release from right atria
The spontaneously beating right atrium (RA) was isolated and
transferred to a preheated (37±0.2 °C), continuously oxygenated
(carbogen: 95% oxygen, 5% CO2), water-jacketed organ bath contain-
ing 3 ml Tyrode solution (NaCl 120, KCl 4.7, MgSO4 1.2, KH2PO4 1.2,
NaHCO3 25, CaCl2 2, and glucose 11 mmol/L, pH 7.4) where the atrium
was pinned ﬂat on a silver stimulating electrode. The method for
determining the local NE release was based on one previously
describedwithmodiﬁcation [9]. Brieﬂy after a 20minute equilibration
period (during which the Tyrode solutionwas replaced every 10 min),
the preparation was incubated for 30 min with 5 μl [3H] NE
(0.185 MBq, Amersham) and ascorbic acid (30 μmol/L, Sigma). To
facilitate the uptake and exchange of [3H] NE into the transmitter store
in pre-synaptic terminal, the atriumwas stimulated at 5 Hz (15 V,1ms
pulse width) for 10 s every 30 s, for 30 min. After that, excess
radioactive NE was washed from the preparation by superfusion with
Tyrode solution for 45min at a rate of 3ml/min. Superfusionwas then
stopped and the bath solution was replaced every 3 min. 0.5 ml
sample from each solution change was added to 4.5 ml scintillation
liquid (Ecoscint A, National Diagnostics) and the amount of radio-
activity (disintegration perminute, DPM)wasmeasured using a liquid
scintillation counter (Tri-Carb 2800TR, Perkin-Elmers Life Science). At
the 16th minute, the atrium was stimulated at 5 Hz for 1 min (ﬁrst
stimulation train, S1). The solutionwas changed at the 27th minute to
one containing a drug (see individual result for identity). A second
stimulation was applied at the 49th minute for 1 min (second
stimulation train, S2). At the end of the experiment, the atrium was
immersed overnight in 4 U/ml papain (Sigma) and the radioactivitycontained in the extract was determined (z). [3H]NE outﬂow was
expressed as a proportional increase using the formula below:
Proportional increase = DPM yð Þ− DPM xð Þ½ =DPM xð Þ × 100k
DPM xð Þ = DPMimmediately before electrical stimulation
DPM yð Þ = DPMimmediately after electrical stimulation:
This method of calculating the [3H]NE was different from our
previous experiment in which the presumed total tissue radioactivity
(z) was used as denominator. However this newer method appears to
be more accurate as it takes into account the reduction of radioactivity
content during the course of the experiment, and obviates the
variability introduced by overnight digestion and subsequent mea-
surement of radioactivity in the tissue extract.
2.4. Post-synaptic beta adrenergic receptor response to exogenous
norepinephrine
Double atria were isolated and transferred to a water-jacketed
organ bath containing 100 ml of Tyrode solution continuously
bubbled with carbogen and maintained at 37±0.2 °C. The left atrium
was attached to a hook at the bottom and the right atrium was
attached to an isometric force transducer (Harvard Apparatus, Model
60-2997) above via 5.0 Mersilk and stretched to ∼0.5 g. The heart rate
was triggered from the contraction and recorded via Biopac System
MP100 connected to a Dell P4 computer run on the AcqKnowledge
3.7.3 software.
After equilibrating for 80 min (during which the Tyrode solution
was changed every 30 min), heart rate responses to NE (cumulative
dose, 0.1–5 μmol/L; Sigma) were assessed in a darkened room. After
the ﬁrst protocol, the double atria preparation was washed with fresh
Tyrode solution for 3 to 4 times (each wash 2 min) so that the heart
rate returned to within 5% of baseline heart rate. After a further
equilibration of 10min, the tissuewas incubatedwith soluble guanylyl
cyclase (sGC) inhibitor, 1H-(1,2,4)oxadiazolo(4,3-a)quinoxaline-1-
one (ODQ) (10 μmol/L; Sigma) for 20 min before responses to NE
was reassessed.
2.5. Plasma L-arg level
Free amino acids from plasma were derivatised using Applied
Biosystems Model 420A PTC derivatiser and then separated (high
performance liquid chromatography) and quantiﬁed with an on-line
Applied Biosystems Model 130A PTC Amino Acid Analyzer. Data was
stored and analysed with a Chameleon® data analysis system.
2.6. Tissue cGMP and cAMP levels
Atrial cGMP level was determined using the Biotrak cGMP [125I]
radioimmunoassay kit from Amersham Biosciences as previously
described [9]. Atrial cAMP level was also determined using Biotrak
cAMP[125I] by employing similar method.
2.7. Western blotting
Left ventricles were cut into small pieces on ice and put into a tube
containing 200 μl of buffer (containing CelLytic buffer and cocktail
protease inhibitor at a ratio of 40:1, Sigma) and 1 mm glass beads
(Biospec). The tissues were homogenised for 90 s (Mini beadbeater-8,
Biospec) and centrifuged (14,000 rpm) for 10 min at 4 °C. The
supernatants were recovered and used for protein analysis and
Western blotting.
15 μg of denatured protein from each sample was loaded into each
well of a Bio-Rad Criterion XT 4–12% polyacrylamide gel. Molecular
Table 1
Animal characteristics.
SHR/not-sup n=19 SHR/sup n=24 WKY/not-sup n=14 WKY/sup n=6
Body weight (g) 336±7 332±8 320±6 311±4
Ventricular weight (g) 1.10±0.03⁎ 1.10±0.03⁎⁎ 0.95±0.02⁎ 0.91±0.01⁎⁎
Ventricular/body weight×100 0.327±0.004⁎ 0.331±0.004⁎⁎ 0.300±0.003⁎ 0.290±0.001⁎⁎
Supplemented L-arg intake (g L-arg/kg body weight/day) – 0.92±0.03 – 0.85±0.03
⁎ pb0.01 for comparison between SHR and WKY (both not-supplemented).
⁎⁎ pb0.01 for comparison between SHR and WKY (both supplemented).
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and standards (where available) were also loaded. The proteins were
separated by electrophoresis and transferred to a polyvinylidene
ﬂuoride membrane (Immobilon-P 0.45 μm, Millipore). The non-
speciﬁc binding sites were blocked with 5% non-fat skim milk in
phosphate buffered saline (Fisher) containing 0.05% Tween-20
(Sigma) (PBST). The membrane was then probed with a primary
antibody (nNOS, Santa Cruz; eNOS, Transduction Laboratory; sGC,
Sigma; TH, Sigma) overnight at 4 °C. On the following day, the
membrane was rinsed twice and then washed 3 times with PBST
(10 min each wash) before incubation with a suitable secondary
antibody conjugated with horseradish peroxidase for 1 h at room
temperature. The membrane was rinsed twice again and washed 3
times with PBST (10 min each wash). The relevant protein signal was
ampliﬁed with luminol based chemiluminescence (Western Lightning
Plus, Perkin Elmer Life Science) and detected using light-sensitive ﬁlm
(CL-XPosure ﬁlm, Pierce). The ﬁlm was digitised and the relative
densities were determined with a computer software (UN-SCAN-IT,
gel 6.1). The results were normalised to β-actin that served as loading
control (detected with mouse anti-β-actin monoclonal antibody,
Abcam).
2.8. nNOS activity assay
The activity of NOS in left ventricles was determined using
NOSdetect® assay kit and protocol from Stratagene. This assay is
based on the conversion of L-arg to L-citrulline by NOS in a
stoichiometric way. L-citrulline can be separated from L-arg using an
ion exchange column/resin. By using a radiolabelled L-arg (universally
labelled 14C, Amersham Bioscience), the rate of its conversion to L-
citrulline was determined by measuring the radioactivity of the
separated labelled fraction of L-citrulline. By performing the assay in
the absence and presence of nNOS inhibitor (N-[(4S)-4-amino-5-[(2-
aminoethyl)amino]pentyl]N′-nitroguanidine, 20 μmol/L, Sigma), theFig. 1. The SHR/not-sup group (n=10) had a signiﬁcantly lower plasma L-arg than
WKY/not-sup group (n=13), but it increased to a comparable level following L-arg
supplementation (n=10). ⁎pb0.01.activities of nNOS could be estimated. The assay was carried out in the
presence of 5 μmol/L arginase inhibitor, N-hydroxy-nor-L-arginine
(Calbiochem) as L-arg can be converted to L-citrulline via alternative
pathway involving arginase [16].
2.9. Statistical analysis
Data are presented as mean±S.E.M. For comparisons amongmore
than 2 groups, one way analysis of variance (ANOVA) was used to
compare the means with post-hoc Tukey's HSD test to assess
individual signiﬁcance. Paired t test was used to compare the results
before (S1) and after application of inhibitor (S2) in the evoked NE
release experiments. Statistical signiﬁcance was accepted at pb0.05.
3. Results
3.1. Animal characteristics
SHR has higher total ventricular weight than WKY and this was
not altered by L-arg feeding (Table 1). No difference in mean arterial
blood pressure or heart rate between supplemented SHR (SHR/sup,
173±6 mmHg, 349±11 bpm; n=13) and non-supplemented SHR
(SHR/not-sup, 180±5 mmHg, 352±7 bpm; n=11) was observed.
Plasma L-arg level was signiﬁcantly lower (pb0.01) in the SHR/not-
sup group (90.5±5.4 μmol/L, n=10) compared with the WKY/not-
sup group (137.2±6.1 μmol/L, n=13) but it increased to a
comparable level following L-arg supplementation (Fig. 1). L-arg
feeding did not increase the plasma L-arg level in the WKY
signiﬁcantly.
3.2. Atrial cGMP and cAMP levels in supplemented and non-
supplemented SHR and WKY
We found that atrial cGMP was lower in the SHR control
group compared with the WKY control group (2.4±0.4 pmol/mg
vs 4.4±0.5 pmol/mg), but increased to 4.1±0.5 pmol/mg
protein (n=10, pb0.05) following L-arg oral supplementationFig. 2. SHR has lower atrial cGMP comparedwithWKY but this was increased with L-arg
feeding. ⁎pb0.05.
Fig. 3. (A) Typical raw data trace from time control experiment (WKY only) showing
measurement of [3H] NE release from isolated right atria in response to 5-Hz electrical
ﬁeld stimulation. S1, S2 and S3 represent the ﬁrst, second and third stimulation
respectively. (B) Proportional [3H]NE increase were similar from S1 to S3 (n=4, all
WKY).
Fig. 4. Non-supplemented SHR (n=19) has higher proportional evoked [3H]NE
increase compared with non-supplemented WKY (n=14). L-arg feeding reduced the
proportional evoked [3H]NE increase in the SHR (n=24, pb0.01) but did not appear to
have signiﬁcant effect on the WKY (n=6). All refer to ﬁrst stimulation, S1. ⁎pb0.01.
Fig. 5. Addition of ODQ increased proportional electrically evoked [3H]NE release (S2) in
both supplemented SHR (n=6) and non-supplemented SHR (n=7), but relatively
more so in the L-arg supplemented group. ⁎pb0.01 with paired t test.
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cAMP levels among the groups (data not shown).
3.3. Proportional evoked NE increase in SHR and WKY
Fig. 3 shows that proportional increase of evoked [3H]NE following
electrical ﬁeld stimulation was stable for the duration of the
experiment. There was no difference among S1, S2 and S3, indicating
that there was no time dependent change (Fig. 3B). Proportional
evoked [3H]NE increase in the non-supplemented SHR (n=19) was
28% higher than the non-supplemented WKY (n=14, pb0.01), but
was reduced with L-arg feeding (n=24, pb0.01) (Fig. 4).
3.4. Soluble guanylyl cyclase inhibitor reversed the effect of L-arg feeding
on NE release in the SHR
Addition of a soluble guanylyl cyclase (sGC) inhibitor, 1H-(1,2,4)
oxadiazolo(4,3-a)quinoxaline-1-one (ODQ, 10 μmol/L, Sigma), to the
organ bath suffusate prior to second stimulation (S2) caused a greater
increase of evoked [3H]NE release in the L-arg fed SHR (n=6)
compared with the non-fed SHR (n=7) (pb0.01 when comparedwith respective S1 in paired t test) such that the two became no
longer signiﬁcantly different (Fig. 5).
3.5. Effects of selective nNOS inhibitor on evoked NE release
Highly selective nNOS inhibitor, N-[(4S)-4-amino-5-[(2-ami-
noethyl)amino]pentyl]N′ nitroguanidine (5 μmol/L, Sigma),
increased proportional evoked [3H]NE release (S2) signiﬁcantly in
supplemented SHR (from 264±22% to 283±25%, n=8), supple-
mented (264±33% to 299±32%, n=6) and non-supplemented
WKY (276±24% to 304±26%, n=10) (pb0.05 when compared
with respective S1 in paired t test), but not in non-supplemented
SHR (from 345±39% to 360±42%, n=8; p=0.17).
3.6. Post-synaptic β1 adrenergic receptor response to exogenous
norepinephrine in SHR
In-vitro heart rate response of the double atrial preparations to
exogenous NE (0.1–5 μmol/L) was similar between L-arg fed (n=13)
and non-fed SHR (n=10), and was not affected by 20 min incubation
with ODQ (10 μmol/L) (Fig. 6).
3.7. Western blotting and nitric oxide synthase activities
We found that non-supplemented SHR had a signiﬁcantly higher
myocardial tyrosine hydroxylase protein compared with non-supple-
mented WKY (pb0.05, n=6 in each). L-arg feeding reduced the
tyrosine hydroxylase in SHR (pb0.05) but not in WKY (n=6 in each)
Fig. 7. (A) Representative bands of tyrosine hydroxylase (TH) and corresponding β-
actin as loading control. (B) Non-supplemented SHR has higher myocardial TH contents
than WKY and supplemented SHR (⁎pb0.05, n=6 for each).
Fig. 6. (A) In-vitro heart rate response of double atrial preparation to exogenous
norepinephrine (0.1–5 μmol/L). (B) Similar result with and without incubation with
ODQ.
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protein levels of eNOS, nNOS or sGC among supplemented and non-
supplemented SHR and WKY (n=6 in each, data not shown). The
nNOS activity measured in-vitro based on L-citrulline conversion was
similar betweennon-supplementedWKY(61±29 fmol L-citrulline/mg
protein/min, n=4), non-supplemented SHR (75±15 fmol L-citrul-
line/mg protein/min, n=6) and supplemented SHR (72±16 fmol
L-citrulline/mg protein/min, n=6) (p=NS).
4. Discussion
There are three novel ﬁndings from this present study. First, we
demonstrated that L-arg supplementation reduced the peripheral
sympathetic hyperactivity in the SHR by attenuating evoked NE
release from the right atria. Secondly, this effect is mediated at least in
part via an increase in the L-arg–NO–cGMP signalling (by augmenting
L-arg availability), and the associated reduction in myocardial tyrosine
hydroxylase protein levels. Finally, the effect of L-arg supplementation
on peripheral cardiac noradrenergic neurotransmission is a pre-
synaptic one, as evidenced by lack of differences between treated and
untreated SHR in in-vitro heart rate responses to exogenous
norepinephrine.
Most published L-arg studies have examined the effect on platelet
aggregation, endothelial function and atheroma formation [12,15,17].
Few studies have assessed its impact on autonomic function, and
these employed intravenous administration that may have confound-
ing non-NO effects such as hormones secretion, pH increase and high
osmolality [14,18,19] secondary to supraphysiological plasma L-arg
concentration. Dietary L-arg supplementation circumvented thesepotential issues as the increase in plasma L-arg level is relatively lower
in the physiological range where this non-NO effect has not been
reported to occur. In this study, we showed that oral L-arg
supplementation could decrease the peripheral cardiac sympathetic
hyperactivity in the SHR to a comparable level seen in the WKY. In
addition, L-arg supplementation increased atrial cGMP to levels
similar to that of the WKY. L-arg is the sole substrate of the enzyme
NOS, with NO as the immediate but labile product. NO in turn activates
sGC to synthesise cGMP, the key secondary messenger of this
signalling system [20]. There is now an abundance of evidence
supporting the notion that the L-arg–NO–cGMP pathway plays an
important neuromodulatory role in cardiac autonomic nervous
system; augmenting the vagal arm and inhibiting the sympathetic
counterpart [21,22]. More importantly in this study, we showed that
bath application of a sGC inhibitor (ODQ) resulted in a higher increase
in the evoked NE release in the L-arg treated SHR than non treated
SHR, suggesting that this pathway had been augmented by L-arg
supplementation. Similarly, the highly selective nNOS inhibitor
increased the evoked NE release (S2) in the supplemented SHR but
not in the non-supplemented SHR when compared with S1. Although
the possibility of a non-NO effect could not be excluded completely,
taken together, these results support the notion that L-arg feeding had
augmented the L-arg–NO–cGMP pathway with a resultant decrease in
evoked NE release. We cannot however, rule out the possibility that
the reduction in evoked NE release may be an indirect result of
enhanced parasympathetic neurotransmission by the augmented
NOS–cGMP pathway. In addition, the conclusion arrived here is
based on ex-vivo data, and therefore it remains to be established
whether this is applicable to the in-vivo setting.
One of the most intriguing and signiﬁcant ﬁndings in this study is
the reduction of myocardial tyrosine hydroxylase level in the SHR
following L-arg supplementation. To our knowledge, this is the ﬁrst
study to demonstrate this feature, although it is known that the SHR
has higher tyrosine hydroxylase contents in key organs when
compared with normotensive controls [23,24]. This observation
provides a link to reduced NE synthesis following L-arg supplementa-
tion in the SHR. One possible explanation is cGMP activating
phosphodiesterase-2 (PDE-2) resulting in increased hydrolysis of
154 C.-W. Lee et al. / Journal of Molecular and Cellular Cardiology 47 (2009) 149–155cAMP [25,26]. PDE-2 is known to exist in myocytes, central nervous
system and stellate ganglia innervating the heart [25,27,28]. Lowering
of cAMP will cause less interaction with cAMP responsive element
domain of tyrosine hydroxylase gene promoter, thus reducing its
expression [29]. However, we did not ﬁnd that atrial cAMP levels were
altered signiﬁcantly by L-arg supplementation in either WKY or SHR
groups. This would suggest that modulation of cAMP levels was not
involved. Nonetheless, we cannot completely rule this out because
localised changes of compartmentalised cAMP, a feature which has
been well described [30,31], would not have been detected by
measurement of total cAMP in atrial tissue.
L-arg levels should not be rate limiting to NO synthesis based on its
pharmacokinetics [10,19]. Despite this, L-arg supplementation has
been shown to improve endothelial function, reduce atherosclerosis
progression, and augment cardiac vagal function; all consistent with
enhanced NO synthesis [14,17]. We believe that this paradoxical
observation, including the result of the current study, can probably be
best explained by NOS compartmentalisation (limiting its access to L-
arg), and a relative L-arg deﬁciency in diseased states from elevated
endogenous NOS inhibitor such as asymmetric dimethylarginine
(ADMA), rather than an absolute one [19,32,33]. We did not measure
ADMA levels in this study although others have shown that plasma
ADMA concentrations are higher in hypertensive subjects than
normotensive ones [34,35]. Interestingly we found that plasma L-arg
level was lower in the SHR when compared with the WKY, but this
was increased to a comparable level following L-arg supplementation.
In addition, we also found that L-arg supplementation had little effect
on the WKY (either evoked NE release or cGMP levels). This was in
keeping with other studies that showed that negative results were
more likely to be obtained when healthy subjects were fed L-arg
[12,19]. It is not entirely clear why there was no signiﬁcant increase in
plasma L-arg in the WKY following supplementation. Increased
breakdown by hepatic arginase (whose activity is dependent on L-
arg concentration) and increased renal excretion (when renal tubular
reabsorption threshold is exceeded) may prevent further increase in
plasma L-arg level beyond a certain set point [36,37]. It is possible that
this set point is close to the normal plasma concentration of L-arg in
WKY, although neither this nor other studies have looked at this
pharmacokinetic question speciﬁcally in rats.
L-arg supplementation did not alter myocardial nNOS, eNOS or sGC
protein levels in the SHR which may seem inconsistent with the
increase in the cGMP brought about by L-arg supplementation.
However, L-arg supplementation served only to provide additional
substrate for NO production which in turn stimulated sGC to generate
more cGMP. nNOS activity was also unchanged in the L-arg treated
SHR, when measured in-vitro; consistent with the overall concept on
the role of L-arg supplementation. We did not measure the amount of
NO produced in-vivo because of its labile nature, but had shown that
L-arg feeding increased themore stable secondarymessenger cGMP in
the SHR.
In the double atrial experiments, we observed that L-arg
supplementation did not affect the heart rate response to exogenous
NE in the SHR. In other words, the effect of L-arg supplementation on
cardiac noradrenergic neurotransmission is a pre-synaptic one and
did not appear to change the post-synaptic beta adrenergic receptor
driven excitability. Gene transfer of nNOS with an adenovirus to the
heart has been found to attenuate evoked NE release, a pre-synaptic
feature, via upregulation of NOS–sGC pathway [9]. It also reduces the
heart rate response of SHR atria to exogenous NE, possibly via NO–
cGMP reducing L-type calcium current in the sinoatrial nodal cells
[38]]. The result of the latter was probably related to the fact that
nNOS gene transfer with a viral vector is a more powerful tool in
augmenting NOS–cGMP pathway, although other non-NO factor could
not be excluded.
Basal heart rate or arterial blood pressure did not differ between
supplemented and non-supplemented SHR when measured underanaesthesia. From published literatures [39–41], it is difﬁcult to
predict whether the result would be different if the measurements
were taken in conscious telemetered rats, given the duration of the
supplementation was for one week only. However, the absence of
difference was consistent with the basal heart rate ﬁndings of the
isolated double atrial preparations. Taken together (including the
evoked NE results), this implied that L-arg, through the NO–cGMP
pathway, probably plays a modulatory role during sympathetic nerve
stimulation rather than under basal resting condition.
4.1. Clinical perspective
L-arg has been used widely as a potential therapeutic tool in both
human and animal studies. Two recent clinical trials on patients with
myocardial infarction have yielded conﬂicting results [42,43]. The
study [43] which was stopped prematurely because of safety concerns
failed to demonstrate any increase in plasma L-arg following
supplementation and did not measure markers of NO production.
This raised the question whether any effects observed could be
conﬁdently attributed to the L-arg treatment. Our study of L-arg
supplementation on the SHR is signiﬁcantly different, because it
demonstrates both an increase in plasma L-arg as well as augmenta-
tion of nNOS–sGC–cGMP pathway with a reduction in evoked NE
release. Moreover the SHR is from a homogenous population; the
same is unlikely for the human subjects. Whether this intervention
could restore autonomic balance and thus improve outcome in
patients with hypertension will require a randomised clinical trial in
a well controlled well selected clinical population. Accumulating
evidence suggest that certain groups such as those with elevated
endogenous NOS inhibitor ADMA and impaired L-arg–NOmetabolism
may be more likely to beneﬁt from L-arg supplementation [44].
Therefore inclusion of such criteria in patient selection for any future
clinical studies may help to ensure a high probability of success.
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ADMA: asymmetric dimethylarginine
cGMP: cyclic guonosine monophosphate




NOS: nitric oxide synthase
eNOS: endothelial nitric oxide synthase
nNOS: neuronal nitric oxide synthase
ODQ: 1H-(1,2,4)oxadiazolo(4,3-a)quinoxaline-1-one
PDE-2: phosphodiesterase-2
sGC: soluble guanylyl cyclase
SHR: spontaneously hypertensive rats
TH: tyrosine hydroxylase
WKY: Wistar Kyoto rats
